XtalPi Holdings Limited
0.74
USD
-0.16
(-17.34%)
ISIN
KYG7S12M1051
CUSIP
G7S12M105
Return %
Stock
S&P 500
1Y
-61.99
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Jian Ma
- Full Time Employees
- 1,254
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Second Phase of the International Shenzhen GD China 518000
- IPO Date
- Jul 7, 2024
- Website
- xtalpi.com
- Similar Companies
- Business
- XtalPi Holdings Ltd (2228.HK), formerly QuantumPharm Inc, is a holding company that develops and provides quantum physics-based, artificial intelligence-powered, and robotics-driven technology platforms for drug discovery, material science research and development solutions, and intelligent laboratory automation services in Mainland China, the United States, Europe, South Korea, Japan, and internationally; its core offerings include XMolGen, an AI small molecule drug discovery computation platform; XtalFold, an antibody-antigen complex structure prediction platform; Xtalgazer, a drug crystallization research and development platform leveraging physical models and AI algorithms for physicochemical properties, crystal structure, and stability predictions; PatSight, an AI-powered patent data extraction tool; XFEP, a tool for affinity predictions between compounds and biological targets; automated chemical synthesis services; discovery chemistry solutions such as hit-to-lead optimization and focused library services; solid-state research encompassing crystal structure determination; AI+robotics laboratory automation solutions featuring modular robots like the NeoDispenser gripper; digital chemistry platforms for patent data extraction and novel chemical space exploration; and PepiX, a peptide and protein R&D platform integrating generative AI design, automated synthesis, trillion-scale libraries, and high-throughput screening; the company was founded in 2015 and is headquartered in Shenzhen, China. Recent developments include the launch of the PepiX platform with preclinical immunogenicity results in cancer vaccine candidates advancing toward clinical trials; strategic partnerships such as a multi-billion dollar collaboration with Professor Gregory Verdine involving up to $5.89 billion in milestone payments; expanded agreements with Pfizer for molecular modeling and simulations; deals with Roche for robotics integration in high-throughput storage and retrieval systems; multi-million dollar arrangements with JW Pharmaceutical for automated synthesis and optimization in oncology and metabolic diseases; a partnership with Liangzhu Laboratory to establish a robotics-powered biomaterials facility; a letter of intent with Baicheng Medicine for AI-driven drug discovery in pain, narcolepsy, oncology, autoimmune diseases, and ophthalmology; and collaborations with DoveTree Medicines and PL Bioscience for pharmaceutical R&D.
Company News
XtalPi Holdings Limited to Announce 2026 Interim Results on August 19, 2026
XtalPi Receives Second Payment from DoveTree; First Oncology Asset Advances into IND-Enabling Studies